Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.

Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR.

Clin Ther. 2004 Apr;26(4):579-89.

PMID:
15189755
2.

Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.

Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.

Clin Drug Investig. 2008;28(10):645-55.

PMID:
18783303
3.

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group.

Eur J Cancer. 2001 Mar;37(5):597-604.

PMID:
11290435
4.

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.

Br J Cancer. 2006 Apr 24;94(8):1122-9.

5.

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.

Value Health. 2011 Jul-Aug;14(5):647-51. doi: 10.1016/j.jval.2011.01.010. Epub 2011 Jun 22.

6.

Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.

Pharmacoeconomics. 2009;27(7):597-608. doi: 10.2165/11310110-000000000-00000.

PMID:
19663530
7.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

8.

Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.

Pettersson K, Carlsson G, Holmberg C, Sporrong SK.

Acta Oncol. 2012 Sep;51(7):840-8. doi: 10.3109/0284186X.2012.713507. Epub 2012 Aug 31.

PMID:
22937953
9.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL; Capecitabine Colorectal Cancer Study Group.

Ann Oncol. 2002 Apr;13(4):566-75.

11.

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Chu E, Schulman KL, McKenna EF Jr, Cartwright T.

Clin Colorectal Cancer. 2010 Oct;9(4):229-37. doi: 10.3816/CCC.2010.n.034.

PMID:
20920995
12.

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.

Chen HH, Chen WT, Lee HC, Lin JK, Fang CY, Chou YH, Lin PC, Lin BW, Huang CC, Yeh CH, Hsu HH, Chen HC, Ting WC, Yang MC, Tan EC.

Qual Life Res. 2015 Feb;24(2):473-84. doi: 10.1007/s11136-014-0773-x. Epub 2014 Aug 7.

PMID:
25099199
13.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group.

J Clin Oncol. 2001 Nov 1;19(21):4097-106.

PMID:
11689577
14.

Costs of treatment of colorectal cancer in different settings in Germany.

Hieke K, Kleeberg UR, Stauch M, Grothey A.

Eur J Health Econ. 2004 Oct;5(3):270-3.

PMID:
15714348
15.

A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.

Maroun J, Asche C, Romeyer F, Mukherjee J, Cripps C, Oza A, Skillings J, Letarte J.

Pharmacoeconomics. 2003;21(14):1039-51.

PMID:
13129416
16.

Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.

Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L.

Drugs. 2008;68(7):949-61. Review.

PMID:
18457461
17.

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.

Tse VC, Ng WT, Lee V, Lee AW, Chua DT, Chau J, McGhee SM.

BMC Cancer. 2011 Jul 9;11:288. doi: 10.1186/1471-2407-11-288.

18.

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.

Tran G, Hack SP, Kerr A, Stokes L, Gibbs P, Price T, Todd C.

Asia Pac J Clin Oncol. 2013 Sep;9(3):239-48. doi: 10.1111/ajco.12044. Epub 2012 Dec 21.

PMID:
23279720
19.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
20.
Items per page

Supplemental Content

Write to the Help Desk